Categories: Clinical TrialNews

ObvioHealth Introduces ObvioGo 2.2: Transforming Study Management with AI-Driven Innovation

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

AI-Driven Enhancements in ObvioGo 2.2 Redefine Efficiency, Compliance, and Innovation in Clinical Trial Management 

NEW YORK, Jan. 14, 2025 /PRNewswire/ — ObvioHealth, a global leader in digital clinical trial solutions, today announced the release of ObvioGo 2.2, the latest version of its innovative platform. This release introduces advanced functionalities designed to streamline study management by leveraging artificial intelligence, enhanced interoperability, and a no-code environment for seamless integration with existing systems and AI models.

ObvioGo 2.2 offers powerful new workflow and task management tools to streamline and enhance trial operations. With real-time compliance tracking and reporting, study teams can proactively identify and address adverse events (AEs), protocol deviations, and compliance risks as they arise, simplifying study management and improving overall efficiency. ObvioGo’s unified platform, now integrating real-time tracking, reporting, and a centralized data repository, unlocks new and novel AI capabilities. It enables seamless integration with existing AI models and the deployment of agentic functionalities, revolutionizing clinical trial efficiency, compliance, and safety.

“ObvioGo 2.2 represents a fundamental shift in clinical trial management, setting a new standard for efficiency and innovation” said Ivan Jarry, CEO of ObvioHealth. “By integrating AI-ready capabilities and seamless connectivity, we are redefining operational efficiency and ensuring data and tasks are organized and accessible for study teams. This release sets a new standard for delivering smarter, faster, and more reliable clinical research outcomes.”

These enhancements simplify the study manager’s role by organizing tasks and data in real-time, paving the way for more efficient and effective trial management. ObvioGo 2.2 underscores ObvioHealth’s commitment to innovation, positioning the company as a leader in AI-driven clinical trial solutions. With its robust capabilities, the platform meets the growing demand for efficient, scalable, and tech-enabled research solutions, delivering significant value to sponsors and advancing the future of clinical research.

About ObvioHealth

ObvioHealth is a global leader in digital clinical trial solutions, delivering smarter, faster, and more cost-effective trials through its innovative ObvioGo platform. By integrating advanced technology with patient-centric design, ObvioHealth ensures high-quality data collection and transformative outcomes.

View original content to download multimedia:https://www.prnewswire.com/news-releases/obviohealth-introduces-obviogo-2-2-transforming-study-management-with-ai-driven-innovation-302349730.html

SOURCE ObvioHealth

Staff

Recent Posts

GE HealthCare drives innovation in theranostics with latest technological advances

GE HealthCare is helping advance clinical and operational excellence in theranostics and molecular imaging through…

14 hours ago

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major…

14 hours ago

Enzon and Viskase Enter into Merger Agreement

Enzon and Viskase stockholders will respectively own approximately 15.9% and 84.1% of the combined companyCRANFORD,…

14 hours ago

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss potential in people…

14 hours ago